SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.

Autor:	Forgacs D; Center for Vaccines and Immunology, University of Georgia, Athens, GA, United States., Jang H; Center for Vaccines and Immunology, University of Georgia, Athens, GA, United States., Abreu RB; Center for Vaccines and Immunology, University of Georgia, Athens, GA, United States., Hanley HB; Center for Vaccines and Immunology, University of Georgia, Athens, GA, United States., Gattiker JL; Center for Vaccines and Immunology, University of Georgia, Athens, GA, United States., Jefferson AM; Center for Vaccines and Immunology, University of Georgia, Athens, GA, United States., Ross TM; Center for Vaccines and Immunology, University of Georgia, Athens, GA, United States.; Department of Infectious Diseases, University of Georgia, Athens, GA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2021 Sep 27; Vol. 12, pp. 728021. Date of Electronic Publication: 2021 Sep 27 (Print Publication: 2021).
DOI:	10.3389/fimmu.2021.728021
Abstrakt:	As the COVID-19 pandemic continues, the authorization of vaccines for emergency use has been crucial in slowing down the rate of infection and transmission of the SARS-CoV-2 virus that causes COVID-19. In order to investigate the longitudinal serological responses to SARS-CoV-2 natural infection and vaccination, a large-scale, multi-year serosurveillance program entitled SPARTA (SARS SeroPrevalence and Respiratory Tract Assessment) was initiated at 4 locations in the U.S. The serological assay presented here measuring IgG binding to the SARS-CoV-2 receptor binding domain (RBD) detected antibodies elicited by SARS-CoV-2 infection or vaccination with a 95.5% sensitivity and a 95.9% specificity. We used this assay to screen more than 3100 participants and selected 20 previously infected pre-immune and 32 immunologically naïve participants to analyze their antibody binding to RBD and viral neutralization (VN) responses following vaccination with two doses of either the Pfizer-BioNTech BNT162b2 or the Moderna mRNA-1273 vaccine. Vaccination not only elicited a more robust immune reaction than natural infection, but the level of neutralizing and anti-RBD antibody binding after vaccination is also significantly higher in pre-immune participants compared to immunologically naïve participants ( p <0.0033). Furthermore, the administration of the second vaccination did not further increase the neutralizing or binding antibody levels in pre-immune participants ( p =0.69). However, ~46% of the immunologically naïve participants required both vaccinations to seroconvert. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Forgacs, Jang, Abreu, Hanley, Gattiker, Jefferson and Ross.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu